Kevin Charles Gorman, Chief Executive Officer at NEUROCRINE BIOSCIENCES INC (NBIX), sold 18,928 shares at $80.80 ($1.5M) on 2022-02-07, disclosed to the SEC on 2022-02-09.
Seasonal sale ($1.5M) by Chief Executive Officer — this insider has traded NBIX in February in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $80.80 | 3,040 | $246K | 16.1% |
| 2 | $80.82 | 3,248 | $263K | 17.2% |
| 3 | $80.82 | 3,248 | $263K | 17.2% |
| 4 | $80.83 | 2,422 | $196K | 12.8% |
| 5 | $80.83 | 2,422 | $196K | 12.8% |
| 6 | $79.49 | 2,274 |
| $181K |
| 11.9% |
| 7 | $79.49 | 2,274 | $181K | 11.9% |
| Total | $80.50 avg | 18,928 | $1.5M | 100% |
| Filing → |
| NBIX | SELL | 2025-08-11 | $26.9M | — | Filing → |
| XNCR | SELL | 2025-06-16 | $29K | — | Filing → |
| NBIX | SELL | 2025-05-29 | $2.3M | — | Filing → |